Reference
Duveau N, et al. Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. Digestive and Liver Disease 49: 163-169, No. 2, Feb 2017. Available from: URL: http://doi.org/10.1016/j.dld.2016.11.002 - France
Rights and permissions
About this article
Cite this article
Adalimumab. Reactions Weekly 1645, 19 (2017). https://doi.org/10.1007/s40278-017-28101-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-28101-3